David Shiba
Hematology & Oncology · Modesto, CANPI 1255389300
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,549 of the $4,600 with a category attached, or 77.1%. It is spread thinly across 24 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,183 and has fallen 90.8% since, to $201 in 2022.
Across 63 payments — averaging $73.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$551
- Johnson & Johnson$473
- Seagen Inc.$376
- Genentech USA, Inc.$343
- Lilly USA, LLC$299
- Amgen$295
- plus $2K from 18 others
Across 2 payments — averaging $140.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$281
What the payments were for
- Food & beverage$3,54977%
- Education$1,05123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $551 |
| Johnson & Johnson | 11 | $473 |
| Seagen Inc. | 4 | $376 |
| Genentech USA, Inc. | 5 | $343 |
| Lilly USA, LLC | 3 | $299 |
| Amgen | 3 | $295 |
| Pfizer | 6 | $277 |
| Astellas Pharma US Inc | 2 | $225 |
| E.r. Squibb & Sons, L.L.C. | 3 | $216 |
| Eisai Inc. | 2 | $213 |
| Novartis | 2 | $198 |
| Incyte Corporation | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $111 |
| Stemline Therapeutics Inc. | 1 | $106 |
| Tesaro, Inc. | 1 | $105 |
| Epizyme, Inc. | 1 | $100 |
| ADC Therapeutics America, Inc. | 1 | $100 |
| Gilead | 1 | $100 |
| Bristol Myers Squibb | 1 | $95 |
| Foundation Medicine, Inc. | 1 | $91 |
| Merck | 1 | $74 |
| Puma Biotechnology, Inc. | 1 | $60 |
| Acrotech Biopharma Inc. | 4 | $52 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,600 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Modesto
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.